These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35579100)

  • 21. Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
    Milberg P; Hilker E; Ramtin S; Cakir Y; Stypmann J; Engelen MA; Mönnig G; Osada N; Breithardt G; Haverkamp W; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):647-54. PubMed ID: 17388913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of Proarrhythmic Potential of Drugs in Optogenetically Paced Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Patel D; Stohlman J; Dang Q; Strauss DG; Blinova K
    Toxicol Sci; 2019 Jul; 170(1):167-179. PubMed ID: 30912807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
    Said TH; Wilson LD; Jeyaraj D; Fossa AA; Rosenbaum DS
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):165-71. PubMed ID: 22561361
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Llopis-Lorente J; Gomis-Tena J; Cano J; Romero L; Saiz J; Trenor B
    J Chem Inf Model; 2020 Oct; 60(10):5172-5187. PubMed ID: 32786710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on the ECG component of the CiPA initiative.
    Vicente J
    J Electrocardiol; 2018; 51(6S):S98-S102. PubMed ID: 30121123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Three-Dimensional Heart Model-Based Screening of Proarrhythmic Potential by
    Hwang M; Han S; Park MC; Leem CH; Shim EB; Yim DS
    Front Physiol; 2019; 10():1139. PubMed ID: 31551815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A deep learning platform to assess drug proarrhythmia risk.
    Serrano R; Feyen DAM; Bruyneel AAN; Hnatiuk AP; Vu MM; Amatya PL; Perea-Gil I; Prado M; Seeger T; Wu JC; Karakikes I; Mercola M
    Cell Stem Cell; 2023 Jan; 30(1):86-95.e4. PubMed ID: 36563695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes.
    Wu Y; Carlsson L; Liu T; Kowey PR; Yan GX
    J Cardiovasc Electrophysiol; 2005 Aug; 16(8):898-904. PubMed ID: 16101634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statistical learning in preclinical drug proarrhythmic assessment.
    Xi NM; Hsu YY; Dang Q; Huang DP
    J Biopharm Stat; 2022 May; 32(3):450-473. PubMed ID: 35771997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Introduction to
    Park JS; Jeon JY; Yang JH; Kim MG
    Transl Clin Pharmacol; 2019 Mar; 27(1):12-18. PubMed ID: 32055576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes.
    Lawrence CL; Bridgland-Taylor MH; Pollard CE; Hammond TG; Valentin JP
    Br J Pharmacol; 2006 Dec; 149(7):845-60. PubMed ID: 17031389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of Drug-Induced Torsades de Pointes Arrhythmia Mechanisms Using hiPSC-CM Syncytial Monolayers in a High-Throughput Screening Voltage Sensitive Dye Assay.
    da Rocha AM; Creech J; Thonn E; Mironov S; Herron TJ
    Toxicol Sci; 2020 Feb; 173(2):402-415. PubMed ID: 31764978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of efficacy of proarrhythmia biomarkers in isolated rabbit hearts with attenuated repolarization reserve.
    Orosz S; Sarusi A; Csík N; Papp JG; Varró A; Farkas S; Forster T; Farkas AS; Farkas A
    J Cardiovasc Pharmacol; 2014 Sep; 64(3):266-76. PubMed ID: 24887684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Occurrence of early afterdepolarization under healthy or hypertrophic cardiomyopathy conditions in the human ventricular endocardial myocyte: In silico study using 109 torsadogenic or non-torsadogenic compounds.
    Christophe B
    Toxicol Appl Pharmacol; 2022 Mar; 438():115914. PubMed ID: 35150662
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Hwang M; Lim CH; Leem CH; Shim EB
    APL Bioeng; 2020 Jun; 4(2):021502. PubMed ID: 32548538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts.
    Sugiyama A
    Br J Pharmacol; 2008 Aug; 154(7):1528-37. PubMed ID: 18552873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress.
    Colatsky T; Fermini B; Gintant G; Pierson JB; Sager P; Sekino Y; Strauss DG; Stockbridge N
    J Pharmacol Toxicol Methods; 2016; 81():15-20. PubMed ID: 27282641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-induced QT prolongation: Concordance of preclinical anesthetized canine model in relation to published clinical observations for ten CiPA drugs.
    Koshman YE; Wilsey AS; Bird BM; Endemann AL; Sadilek S; Treadway J; Martin RL; Polakowski JS; Gintant GA; Mittelstadt SW
    J Pharmacol Toxicol Methods; 2020; 103():106871. PubMed ID: 32360993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beat-to-Beat variability of repolarization determines proarrhythmic outcome in dogs susceptible to drug-induced torsades de pointes.
    Thomsen MB; Volders PG; Beekman JD; Matz J; Vos MA
    J Am Coll Cardiol; 2006 Sep; 48(6):1268-76. PubMed ID: 16979017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.